glp-1 agonists cancer risk The effect of GLP-1R on the medical triad of obesity, diabetes, and | Cancer and Metastasis Reviews No Increased Risk for Thyroid

doi: 10.1194/jlr.M044669

Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies

Eli Lilly, which makes Zepbound, has stated it is considering clinical trials to assess the drug as a treatment for substance use disorders, including alcohol and tobacco dependence

They can be classified by their duration of action: short-acting GLP-1RAs and long-acting GLP-1RAs

While overall persistence continues to decrease among those taking high-potency GLP-1 products after three years, persistence among those taking the drugs over a one-year period improved throughout the span of the study

Quick Stats for GLP-1 Diabetes Treatment Drugs Market GLP-1 Diabetes Treatment Drugs Market Value (2025): USD 6,556.5 million GLP-1 Diabetes Treatment Drugs Market Forecast Value (2035): USD 62,543.2 million GLP-1 Diabetes Treatment Drugs Market Forecast CAGR: 25.3% Leading Drug Type in GLP-1 Diabetes Treatment Drugs Market: Liraglutide (35.5%) Key Growth Regions in GLP-1 Diabetes Treatment Drugs Market: Asia Pacific, North America, and Europe Top Key Players in GLP-1 Diabetes Treatment Drugs Market: Eli Lilly, Sanofi, Novo Nordisk, Hanmi Pharmaceutical Co., Boehringer Ingelheim, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline (GSK), Ganli Pharmaceuticals, Tonghua Dongbao, Shanghai Renhui Biopharmaceuticals Co., Ltd., Huadong Medicine, Page Biopharmaceuticals, Jiangsu Hausen Pharmaceuticals Group Co., Ltd